Tuesday, November 17, 2026

World's First! Patent granted for a biological age estimation method optimized for the Japanese population! Revolutionizing Future Health Management

Social implementation of the research results by Iwate Medical University and its members, for which Epichronos was granted an innovative patent on a Japanese-specific DNA methylation-based method for calculating biological age and assessing aging status. This technology will revolutionize our future health care by "visualizing" an individual's health status and the progress of aging, thereby contributing to the extension of healthy life expectancy and disease prevention.

Provides new criteria for assessing the aging status of individual Japanese

(President: Atsushi Shimizu), which was born out of Iwate Medical University and is pioneering the forefront of anti-aging and personalized healthcare, reported that a patent (Patent No. 7442221) was granted on March 4, 2024 for a method of calculating biological age and a method of evaluating the state of aging by Shimizu and other members of the Bioinformation Analysis Division of the Iwate Medical University Institute of Biomedical and Dental Sciences. (President: Atsushi Shimizu) reported that a patent (Patent No. 7442221) was granted on March 4, 2024.

This patent will revolutionize the calculation of biological age based on DNA methylation (epigenome), optimized for the Japanese, and is medically and academically certain, having been published in the international medical journal, The Lancet Healthy Longevity *1. This patent will lead to the development of social implementation of the measurement of epigenomic age.

The technology by Shimizu et al. for which the patent has been granted provides a method for accurately estimating an individual's biological age through detailed analysis of individual DNA methylation patterns. The patent includes technology that selects between 215 and 235 CpG sites and analyzes the methylation status of these sites to assess an individual's health status and aging progress. This technology has the potential to revolutionize future medicine and health care by improving our understanding of the biological age and aging process of the Japanese population.

Epichronos was established by Professor Atsushi Shimizu, a member of the Department of Bioinformatics at the Institute of Biomedical Research and Innovation, Iwate Medical University, with the aim of implementing the groundbreaking research results of the Tohoku Medical Megabank (TMM) Project in society as a venture company originating from Iwate Medical University. This patent is an important step in the fulfillment of that mission and provides a new method for calculating biological age based on DNA methylation patterns unique to Japanese people.

The DNA methylation age estimation method estimates the biological age of an individual by measuring the methylation status of DNA due to lifestyle and environmental exposure. Unlike estimation methods that have been developed mainly in Europe and the United States, we have developed an epigenomic age estimation method specifically for the Japanese, providing a new standard for assessing the aging status of individuals.
*1 Link:. https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(23)00002-8/fulltext

Epichronos Strengths

Among various methods of measuring epigenomic age, a method of calculating biological age optimized for the Japanese population was patented for the first time in the world.

The inventor of this patent is a core member of EpiCronos, and Shimizu, a leading bioinformatician with more than 10 years of experience in epigenomics research, will serve as its representative.

As a venture originating from a medical university, the company has established relationships with medical institutions and academia, allowing for a variety of collaborations. We are currently discussing with various companies and research institutions to collaborate for social implementation.

Summary of this patent

DNA methylation age (a) and DNA methylation age acceleration (b) calculated from blood using patented method

Developed a model for calculating biological age using DNA methylation information (Figure a)

While the biological age calculation models reported so far have been trained primarily on Western data, the Epichronos model can be said to be a model for the Japanese, trained on Japanese data.

While the existing model uses early Illumina microarray data, this model uses the Common DNA Methylation Variation (CDMV) method, which uses DNA sequence information and selects CpG sites with large inter-individual variation in Japanese, resulting in a completely As a result, we were able to develop a completely new and highly accurate model.

In addition, a formula was developed to evaluate the acceleration of epigenomic age (Figure b)

Japanese people are often seen as younger than their Western counterparts of the same age. Genetic background and lifestyle are assumed to be factors in this, as well as a longer life span, which may lead to a different (slower) progression of epigenomic age.

Therefore, epigenomic age based on existing methods may overestimate the youth of all Japanese, and it is necessary to take into account the aging rate of the population/ethnic group to which the individual belongs in order to evaluate individual aging.

Therefore, we examined the progression of epigenomic age with aging in a Japanese population, and based on this, we developed a formula to evaluate how much the epigenomic age of each individual is accelerating.

This patented technology also contributes to extending healthy life expectancy. Accurate measurement of biological age will enable individuals to identify the risks of aging they face at an early stage and to improve their lifestyle and take appropriate preventive measures. In this way, we aim to contribute to people's health and well-being by providing a new perspective on personal health management and disease prevention.

In close collaboration with Iwate Medical University, we plan to develop various products and services based on this patented technology and provide them widely to society. Specifically, we will contribute to the extension of healthy life expectancy and early detection and prevention of diseases by providing the technology to medical institutions and health checkup centers, as well as developing health management tools for individuals.

EpiCronos, Inc. will continue to research and develop new ways to contribute to people's health and well-being through the power of science and technology. We strongly hope that this patent will be an opportunity to accelerate innovation in the field of health and medicine in the spirit of co-creation with even more researchers and companies.

About Epichronos

Epichronos Corporation is a university-launched venture company established based on the advanced bioinformatics technology of Iwate Medical University. At the forefront of aging research and health science, we are developing innovative methods for calculating biological age and technologies for early detection of diseases using DNA methylation. Aiming to contribute to the extension of people's healthy life expectancy and the early detection and prevention of diseases, we provide products and services based on scientific evidence.

name of companyEpichronos Corporation
EstablishmentAug. 2023
Location15F Toranomon Hills Business Tower, 1-17-1 Toranomon, Minato-ku, Tokyo
representativeAtsushi Shimizu
uniform resouce locatorhttps://epixnos.com/

What is DNA methylation?

It refers to the addition of a methyl group (-CH3) to the C of the base A (adenine), C (cytosine), G (guanine), and T (thymine) that make up DNA, mainly at the site where C and G are aligned (CpG). It is involved in the determination of cell types during development and the regulation of gene expression, and is acquired through lifestyle and exposure to environmental chemicals.

What is DNA methylation age estimation method?

DNA methylation status continues to change throughout life due to lifestyle and environmental exposures. In addition, since changes in DNA methylation status may accumulate over time, DNA methylation status reflects changes in time after birth, i.e., age. Focusing on this feature, methods have been developed to estimate an individual's age (DNA methylation age or epigenomic age) from DNA methylation status.
Conventional DNA methylation age estimation methods have been developed based on data from Westerners, but Iwate Medical University has developed a DNA methylation age estimation method specifically for Japanese people based on DNA methylation information collected in the TMM Project Community Cohort Survey.
DNA methylation age correlates with calendar age, but may be higher or lower than calendar age for each individual. Deviation of DNA methylation age from calendar age has been shown to reflect aging and health status, and is beginning to be used as a health indicator.

PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。